Gowdy Kymberly M, Martinu Tereza, Nugent Julia L, Manzo Nicholas D, Zhang Helen L, Kelly Francine L, Holtzman Michael J, Palmer Scott M
Duke University Medical Center, Durham, NC, 27710, United States.
Duke University Medical Center, Durham, NC, 27710, United States.
Transpl Immunol. 2015 Jan;32(1):51-60. doi: 10.1016/j.trim.2014.10.005. Epub 2014 Nov 5.
Bone marrow transplant (BMT) recipients experience frequent and severe respiratory viral infections (RVIs). However, the immunological mechanisms predisposing to RVIs are uncertain. Therefore, we hypothesized that antiviral T cell immunity is impaired as a consequence of allogeneic BMT, independent of pharmacologic immunosuppression, and is responsible for increased susceptibility to RVI.
Bone marrow and splenocytes from C57BL/6(H2(b)) mice were transplanted into B10.BR(H2(k)) (Allo) or C57BL/6(H2(b)) (Syn) recipients. Five weeks after transplantation, recipient mice were inoculated intranasally with mouse parainfluenza virus type 1 (mPIV-1), commonly known as Sendai virus (SeV), and monitored for relevant immunological and disease endpoints.
Severe and persistent airway inflammation, epithelial injury, and enhanced mortality are found after viral infection in Allo mice but not in control Syn and non-transplanted mice. In addition, viral clearance is delayed in Allo mice as evidenced by prolonged detection of viral transcripts at Day 15 post-inoculation (p.i.) but not in control mice. In concert with these events, we also detected decreased levels of total and virus-specific CD8(+) T cells, as well as increased T cellexpression of inhibitory receptor programmed death-1 (PD-1), in the lungs of Allo mice at Day 8 p.i. Adoptive transfer of CD8(+) T cells from non-transplanted mice recovered from SeV infection into Allo mice at Day 8 p.i. restored normal levels of viral clearance, epithelial repair, and lung inflammation.
Taken together these results indicate that allogeneic BMT results in more severe RVI based on the failure to develop an appropriate pulmonary CD8(+) T cell response, providing an important potential mechanism to target in improving outcomes of RVI after BMT.
骨髓移植(BMT)受者经常发生严重的呼吸道病毒感染(RVI)。然而,导致RVI的免疫机制尚不清楚。因此,我们推测同种异体BMT会导致抗病毒T细胞免疫受损,这与药物性免疫抑制无关,并且是导致对RVI易感性增加的原因。
将C57BL/6(H2(b))小鼠的骨髓和脾细胞移植到B10.BR(H2(k))(同种异体)或C57BL/6(H2(b))(同基因)受体小鼠体内。移植后5周,给受体小鼠鼻内接种1型小鼠副流感病毒(mPIV-1,通常称为仙台病毒(SeV)),并监测相关的免疫和疾病终点。
在同种异体小鼠中,病毒感染后出现严重且持续的气道炎症、上皮损伤和死亡率增加,但在对照同基因小鼠和未移植小鼠中未出现。此外,同种异体小鼠的病毒清除延迟,接种后第15天(p.i.)病毒转录本的检测时间延长可证明这一点,但对照小鼠中未出现这种情况。与这些事件一致的是,在接种后第8天,我们还检测到同种异体小鼠肺中总CD8(+) T细胞和病毒特异性CD8(+) T细胞水平降低,以及抑制性受体程序性死亡-1(PD-1)的T细胞表达增加。在接种后第8天,将从SeV感染中恢复的未移植小鼠的CD8(+) T细胞过继转移到同种异体小鼠中,可恢复病毒清除、上皮修复和肺部炎症的正常水平。
综合这些结果表明,同种异体BMT由于未能产生适当的肺部CD8(+) T细胞反应,导致更严重的RVI,这为改善BMT后RVI的结局提供了一个重要的潜在靶点机制。